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Aggressive fibromatosis of the head and neck: a new
classification based on a literature review over 40 years
(1968-2008)
Abstract
BACKGROUND: Fibromatosis is an aggressive fibrous tumor of unknown etiology that is, in some
cases, lethal. Until now, there has been no particular classification for the head and neck. Therefore, the
aim of the present study was to review the current literature in order to propose a new classification for
future studies. METHODS: An evidence-based literature review was conducted from the last 40 years
regarding aggressive fibromatosis in the head and neck. Studies that summarized patients' data without
including individual data were excluded. RESULTS: Between 1968 and 2008, 179 cases with
aggressive fibromatosis of the head and neck were published. The male to female ratio was 91 to 82
with a mean age of 16.87 years, and 57.32% of the described cases that involved the head and neck
were found in patients under 11 years. The most common localization was the mandible, followed by
the neck. All together, 143 patients were followed up, and in 43 (30.07%), a recurrence was seen.
CONCLUSION: No clear prognostic factors for recurrence (age, sex, or localization) were observed. A
new classification with regard to hormone receptors and bone involvement could improve the
understanding of risk factors and thereby assist in future studies.
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Abstract 
Background Fibromatosis is an aggressive fibrous tumor of unknown etiology that is, 
in some cases, lethal. Until now, there has been no particular classification for the 
head and neck. Therefore, the aim of the present study was to review the current 
literature in order to propose a new classification for future studies.  
Methods An evidence-based literature review was conducted from the last 40 years 
regarding aggressive fibromatosis in the head and neck. Studies that summarized 
patients` data without including individual data were excluded. 
Results Between 1968 and 2008, 179 cases with aggressive fibromatosis of the head 
and neck were published. The male to female ratio was 91 to 82 with a mean age of 
16.87 years, and 57.32% of the described cases that involved the head and neck 
were found in patients under 11 years. The most common localization was the 
mandible, followed by the neck. All together, 143 patients were followed up, and in 43 
(30.07%) a recurrence was seen. 
Conclusion No clear prognostic factors for recurrence (age, sex, or localization) were 
observed. A new classification with regard to hormone receptors and bone 
involvement could improve the understanding of risk factors and thereby assist in 
future studies. 
 
Keywords Aggressive fibromatosis – Head and neck – Fibrous proliferative 
disorders 
 
Introduction 
Fibromatosis is an aggressive fibrous tumor that is characterized by local 
invasiveness and a high recurrence rate. Erosion and invasion of the bone may 
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occur, but metastasizing has not been described. This entity belongs to a group of 
fibrous proliferative disorders including plantar fibromatosis (Dupuytren), penile 
fibromatosis (Peyronie disease), palmar fibromatosis (Ledderhose disease), 
abdominal fibromatosis, and intra-abdominal fibromatosis.[1] 
 
Only 12% of extra-abdominal fibromatoses arise in the head and neck region. One of 
the largest series of head and neck involvements was published by Conley et al. in 
1966.[2] This tumor seems to be more aggressive in the head and neck than those 
arising from the abdominal wall. One reason could be the restricted anatomy, with its 
vital vascular, neural structures contributing to the severity of the clinical 
manifestation, as well as to the recurrence rate following attempts at surgical 
removal. 
 
However, two main classifications for fibromatosis have been introduced, one by 
Allen in 1977 [3] (Table 1) and one by Enziger and Weiss in 1995 [1], which is a 
classification with two subdivisions: superficial (fascial) and deep 
(muscoloaponeurotic) fibromatosis. 
However, no classification has been published so far dealing with fibromatosis of the 
head and neck. Therefore, the aim of the present study was to determine the 
common features of and prognostic factors for this uncommon, but aggressive, 
disease in the head and neck, with the intent to propose a new classification. 
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Classification by Allen[3] 
1. extra-abdominal 
2. abdominal wall desmoids 
3. intra-abdominal desmoids 
4. multiple desmoids 
5. desmoids in Gardner`s syndrome 
Table 1  Classification by Allen[3] 
 
Material and Method 
For the literature review, a search strategy was devised in consultation with a senior 
librarian at the University of Zurich in which electronic databases (Medline and 
Cochrane) were searched using a set of predetermined keywords. The search 
strategy was initially developed and implemented for PubMed, but was revised 
appropriately to suit the other databases. No restriction was placed on the language 
of publication. Studies that summarized patients` data without including individual 
data were excluded. 
 
The citations retrieved from each database were exported into EndNote, which is 
bibliometric management software. Duplicates were discarded. The titles and 
abstracts were screened, and hard copies of all potentially relevant articles were 
retrieved. Their reference lists were manually searched for any related articles.  
 
Results 
Between 1968 and 2008, 179 cases were published dealing with aggressive 
fibromatosis of the head and neck. The male/female ratio was almost 1:1 (91-82) with 
a mean age of 16.87 years (Fig.1). However, 57.32% of the described cases with 
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head and neck involvement were found in patients under 11 years of age. The most 
common localization was the mandible, followed by the neck, but an exact 
localization is difficult to define because of the differentiation in the case reports 
between mandible, submandibular, and neck (Fig. 2). 
Concerning therapy, several strategies have been reported (Fig. 3). In 6 cases 
tamoxifen therapy—because of positive hormone receptors—has been admitted. 
Concerning recurrence rate, an exact comparison is impossible due to different 
follow-up times. 
A total of 143 patients were followed up, and in 43 cases (30.07%), a recurrence was 
seen (Fig. 4), but no correlation with localization was detected. In one patient a 
transformation into a fibrosarcoma occurred [4], and another publication discussed 
the development of a fibrosarcoma.[5]. Invasion of nerves and blood vessels was 
never reported. 
 
Discussion 
The pathogenesis of these nonencapsulated lesions is still unknown; they take their 
origin from fascia, periostium, or musculocaponeuroses.[6]. Desmoid fibromatosis, 
also called aggressive fibromatosis and musculoaponeurotic fibromatosis, can be 
associated with polyposis coli, colonic adenocarcinoma, epidermoid cysts, and 
osteomas; in a very few cases, it can be fatal.[3] 
Some authors have implicated trauma [7] or genetic and endocrine factors in the 
development of these lesions.[8] The terminology was first defined by Stout in 1954 
[9]. Several terms have been used in the literature in order to describe this entity: 
desmoid tumor, desmona, and nonmetastasizing fibrosarcoma.[10]. 
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Differential diagnoses include fibroma, keloid, fibromatosis, fibrosarcoma, and 
myositis proliferans. Concerning myositis proliferans, both diseases present 
infiltration of muscle and in the ligament tissue, draught of fish pattern, but myositis 
proliferans grows faster, presenting more mitoses, and, contrary to aggressive 
fibromatosis, a pleomorphic cell overview [5]. Table 2 presents an overview of the 
immunohistochemical profiles of benign spindle cell lesions. 
Because of the aggressive growth pattern and high cell concentration, this 
classification is based on differentiation between children and adults, but our review 
does not support the conclusion that in children the tumor is more aggressive than in 
adults. 
Concerning incidence, only very few data are available. The estimated incidence in 
the general population is 2 - 4/1,000,000/year.[11] No significant racial or ethnic 
distribution is reported. In children, a fibromatosis incidence of 2.2% is 
mentioned.[12]. A manifestation in the head and neck is reported in 12% of all 
cases.[7] Inguinal fibroblastic and myofibroblastic tumors are present in about 12% of 
soft tissue tumors, and 76% are benign. In 27% of cases, the topography site is the 
head and side of the neck, and 71% occur in the first decade of life[13]. Other 
authors estimate that 34% of all fibromatoses occur in the head and neck. The 
mastoid region is described by some authors as one of the most common 
localizations in the head and neck. This was not supported by our review, in which 
the preferred sites in the head and neck region were mandible and neck. 
Tumors in the oral cavity and paranasal sinus seem to be more aggressive and lethal 
than those on other sides.[7] This fact emphasizes the need for a separate 
classification for this entity. Lakhan et al. reported that approximately 0.03% of all 
neoplasms are desmoid tumors and that they constitute less than 3% of all soft tissue 
tumors[16]. An identification of clonal chromosomal changes has been reported in a 
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significant fraction of cases[17]. Trisomie 8 and 20 in desmoid tumors have been 
discussed[18]. 
Concerning therapy options, several proposals have been reported (Tab. 3), but most 
authors advocate a direct surgical approach; in cases of unresectable tumors 
because of anatomical limits in order to reduce tumor size, some authors have 
suggested chemotherapy. Concerning radiotherapy, only very few results have been 
published. Spear et al. and Posner et al. showed in their studies that radiotherapy, 
added to surgery with residual disease or to surgery for recurrent disease, led to 
significant improvement in local control[19, 20], but there is still controversy 
concerning the dose, particularly in growing children because of possible long-time 
complications. In their study, Spear et al. reported a difference in local control for 
doses <50Gy (36% versus >50Gy (88%))[19]. Chalmers et al. implied some 
interesting points concerning the effect of radiotherapy without surgery[21]. On the 
one hand, surgery and trauma can provide an impetus for tumor development; 
therefore, avoidance of surgery with only radiotherapy could lead to improvement. On 
the other hand, radiotherapy itself could change the tumor behavior. If surgery is 
performed, controversy still surrounds the recommendation for surgical margins: 
Plukker et al. advocate 3-cm margins in adults[22]. Recurrence is described more 
frequently in young patients[3], but our results do not support this theory. 
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 Vimentin Actin S100 Desmin 
Fibromatosis + - - - 
infantile 
myofibromatosis 
+ + - - 
Neurofiboma + - + - 
Leiomyoma + + - + 
nodular fasciitis + + - - 
fibrous 
histiocytoma 
+ +/- - - 
Table 2 Immunohistochemical profiles of fibromatosis and other benign spindle cell 
lesions[11, 12] 
 
1. Surgery 
2. Chemotherapy (Vincristin/Aktinomycin, Cyclophosphamid or 
Methotrexat/Vinblastin)[25] 
3. Hyperthermia 
4. Hormone therapy (antiestrogen)[26] 
5. NSAR therapy[26] 
6. Radiation 
7. Selective tyrosinkinase inhibitor and alpha-interfernon[27] 
8. Combined therapy  
Table 3  Overview of different therapy options 
 
One concern in radiotherapy for children is its negative influence on growth, leading 
to possible deformities.  
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The possibility of non-surgical treatment is interesting in particular for tumors 
localized in anatomically difficult structures that need to be preserved as much as 
possible, e. g., the sinuses. On the other hand, one has to keep in mind the potential 
toxicity associated with the systemic application of chemotherapy. Surgical resection 
that results in tumor-free margins and a function-preserving approach are the goals.  
Therefore, some authors advocate an estrogen receptor test on the tissue sample in 
order to provide tamoxifen therapy because spontaneous regression has been 
observed in the menarche and menophase[23]. One reason seems to be the ability 
of antiestrogen compounds in vitro to stimulate the secretion of transforming growth 
factor beta (TGFb) by stromal fibroblasts, leading to inhibiting the growth of 
surrounding epithelial cells. Benson and Baum [24] hypothesize that in aggressive 
fibromatosis, the tissue may consist of immature fibroblasts with a fetal phenotype 
characterized by a negative growth response to TGFb, but the short and long-term 
toxicity to children (with regard to growth, puberty) resulting from this hormonal 
therapy must be considered. In women that have been treated with tamoxifen for 
breast cancer, an increased probability for incidence of endometrial carcinomas is 
discussed. 
In recent times, some authors have advocated another therapy option with interferon 
alpha for disease stabilization because IFN type I seems to be a positive regulator of 
neoplastic growth.[25, 26]. Another therapy option could be tyrosine kinase inhibitor 
imatinib due to tumor expression of activated receptor tyrosine kinase c-kit and/or 
platelet-derived growth factor receptor alpha[27]. 
 
Controversy also surrounds radiotherapy. Some authors advocate this therapy 
option[28], whereas others doubt the effect, in particular at high doses because of 
side effects. The problem concerning all these therapy options seems to be the lack 
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of experience in using them for head and neck fibromatosis; it seems to be more 
common to use these strategies in intra-abdominal manifestations where resections 
can be difficult because of the diffuse infiltration. 
Some authors prefer a radical neck dissection for all neck fibromatoses in order to 
reduce recurrence rates by 33% through aggressive surgery[29], but since 
aggressive fibromatosis do not metastasize and because the recurrence rate is 
higher in young patients, one should be careful with the indication for a radical neck 
dissection. 
The only factor for recurrence-free follow-up seems to be negative margins[16, 30, 
31]. On the other hand, some authors claim that recurrence seems to be independent 
of the margin status [33, 33], and a margin of less than 1mm did not adversely affect 
outcome when compared with more generous margins.  
Our results show that the probability for recurrence seems to be independent of age 
or localization (Fig. 5). Other researchers have included as prognostic factors an age 
of less than 18 years, recurrent disease, and treatment with surgery alone[19]. 
Concerning localization, Scougall et al.[34] showed that there are no differences in 
the outcome between children and adults. 
 
Because of missing correlations among the localization, age, and recurrence rates, 
we propose a new classification for this entity in order to evaluate further cases (Fig. 
6). 
 
Conclusion 
No clear prognostic factors for recurrence (age, sex, or localization) were observed. 
A new classification with regard to hormone receptors and bone involvement could 
improve the understanding of risk factors clinically and for future studies. 
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Fig. 1 Age distribution  
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Fig. 2 Distribution of localization  
 
 
 
Fig. 3 Distribution of therapy  
 
 
Fig. 4 Age distribution of recurrence  
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Fig. 5 Distribution of recurrence in relation to localization  
 
 
 
Fig. 6 Proposal for new classification  
 
